Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma

Histopathology

Volumn 63, Issue 2, 2013, Pages 187-193

  Adackapara, Cheryl A ^a   Sholl, Lynette M ^a   Barletta, Justine A ^a   Hornick, Jason L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BRAF; Colon cancer; KRAS; Predictive markers; Targeted therapy

Indexed keywords

B RAF KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY VE1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURGERY; COHORT ANALYSIS; COLORECTAL CARCINOMA; CYTOPLASM; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

EID: 84880725363     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12154     Document Type: Article

References (40)

1. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011; 60; 397-411.
2. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008; 26; 1626-1634.
3. Richman SD, Seymour MT, Chambers P et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J. Clin. Oncol. 2009; 27; 5931-5937.
4. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008; 26; 5705-5712.
5. Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med. Chem. 2012; 12; 163-171.
6. Barault L, Veyrie N, Jooste V et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int. J. Cancer 2008; 122; 2255-2259.
7. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007; 357; 2040-2048.
8. Benson AB 3rd, Bekaii-Saab T, Chan E et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN guidelines. J. Natl. Compr. Canc. Netw. 2013; 11; 141-152.
9. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 2009; 361; 2449-2460.
10. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483; 100-103.
11. Laurent-Puig P, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 2009; 27; 5924-5930.
12. Bronte G, Cicero G, Cusenza S et al. Monoclonal antibodies in gastrointestinal cancers. Expert Opin. Biol. Ther. 2013; 13; 889-900.
13. De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304; 1812-1820.
14. Huang CS, Farraye FA, Yang S, O'Brien MJ. The clinical significance of serrated polyps. Am. J. Gastroenterol. 2011; 106; 229-240.
15. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann. Oncol. 2010; 21; 2396-2402.
16. Tran B, Kopetz S, Tie J et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117; 4623-4632.
17. Maughan TS, Adams RA, Smith CG et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377; 2103-2114.
18. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 2011; 29; 2011-2019.
19. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 2012; 7; e47054.
20. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11; 753-762.
21. Bokemeyer C, Van Cutsem E, Rougier P et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 2012; 48; 1466-1475.
22. Jin M, Hampel H, Zhou X, Schunemann L, Yearsley M, Frankel WL. BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome. Am. J. Clin. Pathol. 2013; in press.
23. Lagerstedt Robinson K, Liu T, Vandrovcova J et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J. Natl Cancer Inst. 2007; 99; 291-299.
24. Pai RK, Jayachandran P, Koong AC et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am. J. Surg. Pathol. 2012; 36; 744-752.
25. Washington MK, Berlin J, Branton P et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch. Pathol. Lab. Med. 2009; 133; 1539-1551.
26. Koperek O, Kornauth C, Capper D et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am. J. Surg. Pathol. 2012; 36; 844-850.
27. Long GV, Wilmott JS, Capper D et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am. J. Surg. Pathol. 2013; 37; 61-65.
28. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012; 62; 10-29.
29. Van Cutsem E, Kohne C, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009; 360; 1408-1417.
30. Karapetis CS, Khambata-Ford S, Jonker D et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008; 359; 1757-1765.
31. Behl AS, Goddard KA, Flottemesch TJ et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J. Natl Cancer Inst. 2012; 104; 1785-1795.
32. Ilie M, Long E, Hofman V et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann. Oncol. 2013; 24; 742-748.
33. Colomba E, Helias-Rodzewicz Z, Von Deimling A et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J. Mol. Diagn. 2013; 15; 94-100.
34. Capper D, Berghoff AS, Magerle M et al. Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012; 123; 223-233.
35. Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am. J. Surg. Pathol. 2012; 36; 1796-1800.
36. Bosmuller H, Fischer A, Pham DL et al. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum. Pathol. 2013; 44; 329-335.
37. Adackapara CA, Howitt BE, Sholl LM, Krane JF, Hornick JL, Barletta JA. BRAF V600E mutation-specific monoclonal antibody is predictive of BRAF mutation status determined by genotyping in papillary thyroid carcinoma [abstract]. Mod. Pathol. 2013; 26; 129A.
38. Foreman RK, Sholl LM, Barletta JA, Hornick JL. VE1 is a sensitive and specific marker for BRAF V600E mutations in melanoma [abstract]. Mod. Pathol. 2013; 26; 114A.
39. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011; 364; 2507-2516.
40. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012; 367; 1694-1703.